AR028487A1 - Tratamiento de la endometriosis o infertilidad o mejoramiento de la fertilidad - Google Patents

Tratamiento de la endometriosis o infertilidad o mejoramiento de la fertilidad

Info

Publication number
AR028487A1
AR028487A1 ARP000105228A ARP000105228A AR028487A1 AR 028487 A1 AR028487 A1 AR 028487A1 AR P000105228 A ARP000105228 A AR P000105228A AR P000105228 A ARP000105228 A AR P000105228A AR 028487 A1 AR028487 A1 AR 028487A1
Authority
AR
Argentina
Prior art keywords
endometriosis
infertility
fertility
improvement
treatment
Prior art date
Application number
ARP000105228A
Other languages
English (en)
Inventor
William J Bologna
Dominique De Ziegler
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR028487A1 publication Critical patent/AR028487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con composiciones y métodos para utilizar un agonista beta-adrenérgico para tratar la endometriosis, para tratar la infertilidad, y para mejorar la fertilidad. La presente invencion además se relaciona con formular tal composicion o método de manera que tal que se suministren niveles terapéuticamente suficientes del agonista beta-adrenérgico en forma localizada a la vez que se evitan las concentraciones sistémicas adversas en el huésped, con lo que se minimizan o evitan los efectos secundarios adversos.
ARP000105228A 1999-10-05 2000-10-04 Tratamiento de la endometriosis o infertilidad o mejoramiento de la fertilidad AR028487A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15775499P 1999-10-05 1999-10-05
US66838400A 2000-09-25 2000-09-25

Publications (1)

Publication Number Publication Date
AR028487A1 true AR028487A1 (es) 2003-05-14

Family

ID=26854456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105228A AR028487A1 (es) 1999-10-05 2000-10-04 Tratamiento de la endometriosis o infertilidad o mejoramiento de la fertilidad

Country Status (28)

Country Link
EP (1) EP1220667B1 (es)
JP (2) JP2003510354A (es)
KR (1) KR100738724B1 (es)
CN (1) CN1218694C (es)
AR (1) AR028487A1 (es)
AT (1) ATE271860T1 (es)
AU (1) AU780736B2 (es)
BR (1) BR0014548A (es)
CA (1) CA2385974C (es)
CO (1) CO5251423A1 (es)
DE (1) DE60012554T2 (es)
DK (1) DK1220667T3 (es)
ES (1) ES2223581T3 (es)
GE (1) GEP20043313B (es)
HK (1) HK1044120B (es)
HU (1) HU225990B1 (es)
IL (2) IL148784A0 (es)
MA (1) MA25501A1 (es)
MX (1) MXPA02003453A (es)
MY (1) MY129518A (es)
NO (1) NO329663B1 (es)
NZ (1) NZ518429A (es)
PE (1) PE20010742A1 (es)
PT (1) PT1220667E (es)
TR (1) TR200200899T2 (es)
TW (1) TWI280877B (es)
UA (1) UA74168C2 (es)
WO (1) WO2001024788A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101327326A (zh) * 2001-10-29 2008-12-24 哥伦比亚实验室(百慕大群岛)有限公司 阴道给药治疗骨盆痛和不孕症的抗节律障碍剂
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
SG10201504913UA (en) * 2010-03-22 2015-07-30 Repros Therapeutics Inc Compositions and methods for non-toxic delivery of antiprogestins
KR101010031B1 (ko) * 2010-12-08 2011-01-21 류상범 흡수식 냉온수기용 엘리미네이터
IN2014DN10548A (es) 2012-05-31 2015-08-21 Repros Therapeutics Inc
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241087A (en) * 1979-04-02 1980-12-23 William H. Rorer, Inc. Dysmenorrhea treatment
AU5068090A (en) * 1989-03-07 1990-09-13 Adeza Biomedical Corporation Endometriosis diagnosis methods and reagents
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen

Also Published As

Publication number Publication date
IL148784A (en) 2006-12-31
DE60012554D1 (de) 2004-09-02
PE20010742A1 (es) 2001-07-19
AU7525000A (en) 2001-05-10
JP2010018639A (ja) 2010-01-28
HK1044120A1 (en) 2002-10-11
CO5251423A1 (es) 2003-02-28
MY129518A (en) 2007-04-30
NO20021591L (no) 2002-05-28
HUP0203050A3 (en) 2006-02-28
MA25501A1 (fr) 2002-07-01
KR100738724B1 (ko) 2007-07-12
ATE271860T1 (de) 2004-08-15
NZ518429A (en) 2004-02-27
PT1220667E (pt) 2004-11-30
DK1220667T3 (da) 2004-12-06
NO329663B1 (no) 2010-11-29
NO20021591D0 (no) 2002-04-04
EP1220667B1 (en) 2004-07-28
KR20020062285A (ko) 2002-07-25
CA2385974C (en) 2010-01-26
HU225990B1 (en) 2008-02-28
WO2001024788A3 (en) 2001-12-06
EP1220667A2 (en) 2002-07-10
MXPA02003453A (es) 2002-08-20
CN1377264A (zh) 2002-10-30
CA2385974A1 (en) 2001-04-12
BR0014548A (pt) 2002-06-04
GEP20043313B (en) 2004-03-10
ES2223581T3 (es) 2005-03-01
JP2003510354A (ja) 2003-03-18
HK1044120B (zh) 2004-12-17
TR200200899T2 (tr) 2002-07-22
AU780736B2 (en) 2005-04-14
IL148784A0 (en) 2002-09-12
WO2001024788A2 (en) 2001-04-12
DE60012554T2 (de) 2005-11-24
UA74168C2 (uk) 2005-11-15
CN1218694C (zh) 2005-09-14
HUP0203050A2 (hu) 2003-02-28
TWI280877B (en) 2007-05-11

Similar Documents

Publication Publication Date Title
AR023129A1 (es) Composiciones para mejorar la fertilidad
AR028487A1 (es) Tratamiento de la endometriosis o infertilidad o mejoramiento de la fertilidad
PA8523201A1 (es) Nueva composicion farmaceutica
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
EA199900487A2 (ru) Интраназальные композиции для лечения сексуальных расстройств
ES2171888T3 (es) Composicion de aditivo para liberar un agente beneficioso y pastillas limpiadoras que contienen dichos aditivos.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
GT200900142A (es) Combinacion de los inhibidores iap y flt3 inhibidores
UY26889A1 (es) Compuestos farmacéuticos
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
UY27800A1 (es) Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata.
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
PA8571901A1 (es) Nueva composicion farmaceutica
GT200000194A (es) Quimioterapia de combinacion.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
MXPA05008347A (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.

Legal Events

Date Code Title Description
FB Suspension of granting procedure